Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vardenafil hydrochloride 是口服具有活性的、高效的、选择性的磷酸二酯酶 5抑制剂。它对 PDE1 (180 nM),PDE6 (11 nM),PDE2,PDE3,PDE4 (<1000 nM) 具有选择性。它能够非竞争性地抑制环磷酸鸟苷水解,提高 cGMP 水平。它可用于勃起功能障碍的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 286 | 现货 | ||
10 mg | ¥ 397 | 现货 | ||
25 mg | ¥ 672 | 现货 | ||
50 mg | ¥ 989 | 现货 | ||
100 mg | ¥ 1,460 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 379 | 现货 |
产品描述 | Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes |
靶点活性 | PDE6:11 nM (IC50), PDE5:0.7 nM (IC50), PDE1:180 nM (IC50) |
体内活性 |
After 12 weeks of treatment, a dose-dependent (P = 0.02) improvement in erections was noted for the GAQ, with 57 and 72% of men taking 10 mg or 20 mg vardenafil, respectively, reporting improved erections, in contrast to 13% after taking placebo (P < 0.0001). For the erectile function domain, dose-dependent (P = 0.03) final scores for the 10- and 20-mg dose were 17.1 and 19.0 compared with 12.6 for placebo (P < 0.0001). Both vardenafil doses significantly enhanced the rates of successful penetration (P < 0.0001) and successful intercourse (P < 0.0001) compared with placebo. Vardenafil treatment was effective in increasing intercourse success rates at all levels of baseline ED severity, at each level of plasma HbA(1c), and for type 1 and 2 diabetes. Treatment-emergent adverse events were primarily mild to moderate headache ( |
别名 | 伐地那非, 盐酸伐地那非 |
分子量 | 525.06 |
分子式 | C23H33ClN6O4S |
CAS No. | 224785-91-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (190.45 mM), Sonification is recommended.
H2O: 100 mg/mL (190.45 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 1.9045 mL | 9.5227 mL | 19.0454 mL | 47.6136 mL |
5 mM | 0.3809 mL | 1.9045 mL | 3.8091 mL | 9.5227 mL | |
10 mM | 0.1905 mL | 0.9523 mL | 1.9045 mL | 4.7614 mL | |
20 mM | 0.0952 mL | 0.4761 mL | 0.9523 mL | 2.3807 mL | |
50 mM | 0.0381 mL | 0.1905 mL | 0.3809 mL | 0.9523 mL | |
100 mM | 0.019 mL | 0.0952 mL | 0.1905 mL | 0.4761 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vardenafil hydrochloride 224785-91-5 Metabolism PDE 伐地那非 Vardenafil Hydrochloride PDE-5 inhibitors Vardenafil Endogenous Metabolite diabetes Zucker diabetic fatty (ZDF) rats dysfunction erectile dysfunction Pharmacokinetics Phosphodiesterase (PDE) inhibit selective Impotence Inhibitor smooth erectile 盐酸伐地那非 muscle stimulation cGMP hepatitis inhibitor